<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04491266</url>
  </required_header>
  <id_info>
    <org_study_id>20-13</org_study_id>
    <nct_id>NCT04491266</nct_id>
  </id_info>
  <brief_title>Tolerability and Modulatory Action of the Butyrate Releaser N-(1-carbamoyl-2-phenyl-ethyl) Butyramide</brief_title>
  <official_title>Tolerability and Modulatory Action on Neonatal Gastrointestinal Function and Immunity of the Butyrate Releaser N-(1-carbamoyl-2-phenyl-ethyl) Butyramide as New Component for Infant Formula</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Accumulating evidence is showing that gut microbiota could play a key role in&#xD;
      gastrointestinal tract and immune system development and function. Many beneficial effects&#xD;
      elicited by gut microbiota are mediated its metabolites. Short chain fatty acids (SCFAs) are&#xD;
      major metabolites produced by gut microbiota. Among SCFA, butyrate has emerged as pivotal&#xD;
      regulator of many gastrointestinal function and immune system development and function.&#xD;
&#xD;
      Butyrate is produced by intestinal microbial fermentation of resistant starches and dietary&#xD;
      fiber. It regulates several beneficial intestinal and extra-intestinal functions, among the&#xD;
      first it serves as the primary energy source for the gut epithelium, increases mineral&#xD;
      absorption, stimulates proliferation and differentiation of normal colon epithelial cells,&#xD;
      improves the gut barrier function by stimulation of the formation of mucin, antimicrobial&#xD;
      peptides, and tight-junction proteins, interacts with the immune system and has&#xD;
      anti-inflammatory effects.&#xD;
&#xD;
      Butyrate also seems to regulate the expression of antimicrobial peptides in particular&#xD;
      upregulating transcription of cathelicidin thanks to his action of histone deacetylase&#xD;
      inhibitor and it has been shown to induce human β-defensin 2 (HBD-2) mRNA expression in&#xD;
      colonocytes, although there are few publications reporting its regulation of defensins (Berni&#xD;
      Canani R et al. W J Gastroenterol. 2011;17(12):1519). Preliminary data showed that breast&#xD;
      milk contains butyrate. Butyrate could be an ideal compound for infant formulas for an&#xD;
      efficient regulation of a number of protective actions at gastrointestinal tract level and at&#xD;
      systemic level.&#xD;
&#xD;
      A new butyrate releaser, useful for all the known applications of butyrate, presenting&#xD;
      physiochemical characteristics suitable for easy oral administration (free from unpleasant&#xD;
      organoleptic properties of butyrate): N-(1-carbamoyl-2-phenyl-ethyl) butyramide (FBA) has&#xD;
      been developed. The molecule is a butyrate amide with the amino acid phenylalanine, solid,&#xD;
      odourless, tasteless, stable at gastric pH, and able to release butyrate constantly&#xD;
      throughout gastrointestinal tract.&#xD;
&#xD;
      The aim of the study was to evaluate tolerability and safety profile of a nutritional&#xD;
      intervention with FBA in formula fed at term neonates. The effects on the expression of&#xD;
      innate immunity biomarkers as well as on neonatal gut function were also assessed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 9, 2012</start_date>
  <completion_date type="Actual">December 31, 2013</completion_date>
  <primary_completion_date type="Actual">December 31, 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerability: adverse events</measure>
    <time_frame>up to 28 days</time_frame>
    <description>number and proportion of subjects with adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>percentage of subjects with infantile colics</measure>
    <time_frame>up to 28 days</time_frame>
    <description>rate of subjects with infantile colics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>daily number of bowel movements</measure>
    <time_frame>up to 28 days</time_frame>
    <description>daily number of bowel movements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stool consistency</measure>
    <time_frame>up to 28 days</time_frame>
    <description>stool consistency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>daily number of regurgitation episodes</measure>
    <time_frame>up to 28 days</time_frame>
    <description>daily number of regurgitation episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fecal levels of of β-defensins 2 (HβD-2)</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of secretory immunoglobulin A (sIgA)</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Safety Issues</condition>
  <arm_group>
    <arm_group_label>FBA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-(1-carbamoyl-2-phenyl-ethyl) butyramide (FBA) has been developed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>maltodextrins</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>FBA</intervention_name>
    <description>N-(1-carbamoyl-2-phenyl-ethyl) butyramide (FBA) has been developed.</description>
    <arm_group_label>FBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>maltodextrins</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  otherwise healthy formula fed-neonates&#xD;
&#xD;
          -  born at term (&gt;37 gestational age)&#xD;
&#xD;
          -  adequate weight for gestational age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  twins,&#xD;
&#xD;
          -  infants with history of severe asphyxia,&#xD;
&#xD;
          -  meconium aspiration syndrome,&#xD;
&#xD;
          -  immunodeficiency,&#xD;
&#xD;
          -  congenital infections,&#xD;
&#xD;
          -  genetic diseases and chromosomal abnormalities,&#xD;
&#xD;
          -  malformations,&#xD;
&#xD;
          -  insufficient reliability or presence of conditions that made the patient's compliance&#xD;
             with the protocol unlikely,&#xD;
&#xD;
          -  infants with any other condition which, in the opinion of the Investigator, is likely&#xD;
             to interfere with the ability of the infant to ingest food, or the normal growth and&#xD;
             development of the infant, or the evaluation of the infant.&#xD;
&#xD;
        In addition, as maternal exclusion factors:&#xD;
&#xD;
          -  history of immune diseases,&#xD;
&#xD;
          -  tumors,&#xD;
&#xD;
          -  infectious or inflammatory diseases that required antibiotic therapy during pregnancy,&#xD;
&#xD;
          -  diabetes,&#xD;
&#xD;
          -  gestosis,&#xD;
&#xD;
          -  dyslipidemia,&#xD;
&#xD;
          -  positive vaginal swab for Group B Streptococcus,&#xD;
&#xD;
          -  prolonged rupture of membranes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Naples Federico II</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 25, 2020</study_first_submitted>
  <study_first_submitted_qc>July 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2020</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Roberto Berni Canani</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

